A Follow-up Study of Immune Dysregulation in Patients With COVID-19

Last updated: April 26, 2023
Sponsor: Qilu Hospital of Shandong University
Overall Status: Active - Recruiting

Phase

N/A

Condition

Organ Transplant

Covid-19

Treatment

N/A

Clinical Study ID

NCT05669248
Qilu-20221224-pang
  • Ages > 18
  • All Genders

Study Summary

In order to detect the immunosuppression status of COVID-19 patients, this study collected blood samples of COVID-19 patients on the 10th, 20th and 30th days after the onset of symptoms, and detected the proinflammatory, anti-inflammatory factors，immunosuppressive marker，immune cells in the blood samples to evaluate the immunosuppression status of COVID-19 patients.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Participant is diagnosed with symptomatic COVID-19 by a positive PCR for SARS-CoV-2 orantigen quicktest.
  2. Study participant is 18 years of age or older

Exclusion

Exclusion Criteria:

  1. Patients with immunosuppression, including HIV infection, hematopoietic stem celltransplantation and high-dose immunosuppressant therapy
  2. Pregnancy or breastfeeding
  3. Patients receiving chemotherapy or other cancer treatment

Study Design

Total Participants: 200
Study Start date:
January 03, 2023
Estimated Completion Date:
December 31, 2023

Study Description

After SARS-CoV-2 infection, the patient's immune system is overactivated. While the immune cells release a large number of proinflammatory factors, anti-inflammatory response starts at the same time. Anti-inflammatory factors such as IL-4, IL-10, and IL-37 will be compensated to resist the release of proinflammatory factors and prevent the further development of systemic inflammatory response. However, when the anti-inflammatory factor is excessively released, it will cause compensatory response syndrome, leading to immunosuppression. Whether the level of anti-inflammatory factors continues to rise, and whether it will lead to the persistence of later immunosuppression is unknown. Therefore, this study intends to recruit COVID-19 patients, detect the pro-inflammatory and anti-inflammatory factors，immunosuppressive marker，immune cells in 10 days, 20days, and 30days after the symptoms appear, and evaluate the immunosuppression status of patients with COVID-19

Connect with a study center

  • Qilu Hospital of Shandong University

    Jinan, Shandong 250012
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.